GoldenGolden

PCSK9

Protein-coding gene in the species homo sapiens

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Bob Yirka
May 21, 2021
phys.org
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol in the blood of test monkeys. In their paper published in the journal Nature, the researchers describe their technique.
BioSpace
May 11, 2021
BioSpace
Verve Therapeutics announced the presentation of additional preclinical data from the company's gene editing programs for the treatment of atherosclerotic cardiovascular disease, the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy 24th Virtual Annual Meeting.
BioSpace
May 5, 2021
BioSpace
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio),
Angus Liu
April 21, 2021
FierceBiotech
Scientists at AstraZeneca have early data showing that an experimental antibody drug increases "good" HDL cholesterol in monkeys and people. Combining the drug with a PCSK9 inhibitor appeared to have a synergistic effect.
Arlene Weintraub
February 19, 2021
FierceBiotech
Precision BioSciences' gene editing technique produced a stable lowering of PCSK9 protein and LDL cholesterol in nonhuman primates for three years, according to a study led by University of Pennsylvania researchers. The company is developing the one-time treatment as an alternative to drug treatments for familial hypercholesterolemia.
Ionis Pharmaceuticals, Inc.
November 30, 2020
www.prnewswire.com:443
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical...
Ionis Pharmaceuticals, Inc.
November 13, 2020
www.prnewswire.com:443
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce...
Amgen
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA)...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.